Agios Pharmaceuticals (NASDAQ:AGIO) CFO Cecilia Jones Sells 2,932 Shares

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) CFO Cecilia Jones sold 2,932 shares of the business’s stock in a transaction dated Tuesday, December 30th. The shares were sold at an average price of $27.09, for a total value of $79,427.88. Following the completion of the sale, the chief financial officer directly owned 37,394 shares of the company’s stock, valued at approximately $1,013,003.46. This represents a 7.27% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Agios Pharmaceuticals Stock Down 0.1%

NASDAQ:AGIO opened at $27.18 on Friday. The company has a market cap of $1.58 billion, a PE ratio of -3.88 and a beta of 0.89. The business’s 50 day moving average is $32.20 and its two-hundred day moving average is $35.96. Agios Pharmaceuticals, Inc. has a 52 week low of $22.24 and a 52 week high of $46.00.

Agios Pharmaceuticals (NASDAQ:AGIO) last posted its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported ($1.78) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.93) by $0.15. Agios Pharmaceuticals had a negative return on equity of 28.35% and a negative net margin of 895.86%.The business had revenue of $12.88 million for the quarter, compared to analyst estimates of $10.49 million. During the same period in the prior year, the company posted $16.22 EPS. The business’s revenue was up 43.3% compared to the same quarter last year. As a group, sell-side analysts expect that Agios Pharmaceuticals, Inc. will post -6.85 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on the stock. Truist Financial raised their price target on shares of Agios Pharmaceuticals from $32.00 to $38.00 and gave the stock a “buy” rating in a research report on Wednesday, December 24th. Citigroup reissued a “buy” rating on shares of Agios Pharmaceuticals in a report on Friday, December 26th. Wall Street Zen lowered Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, November 22nd. Bank of America increased their price target on Agios Pharmaceuticals from $32.00 to $34.00 and gave the stock a “buy” rating in a research report on Wednesday, December 24th. Finally, Weiss Ratings restated a “sell (d)” rating on shares of Agios Pharmaceuticals in a research report on Monday. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, four have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $38.89.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of AGIO. First Horizon Corp acquired a new position in shares of Agios Pharmaceuticals during the third quarter valued at $45,000. NewEdge Advisors LLC bought a new position in Agios Pharmaceuticals in the 1st quarter valued at about $40,000. Quantbot Technologies LP acquired a new position in Agios Pharmaceuticals during the 3rd quarter valued at about $79,000. Mirae Asset Global Investments Co. Ltd. raised its position in shares of Agios Pharmaceuticals by 16.7% during the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,237 shares of the biopharmaceutical company’s stock worth $74,000 after buying an additional 320 shares in the last quarter. Finally, PNC Financial Services Group Inc. lifted its stake in shares of Agios Pharmaceuticals by 23.4% in the 2nd quarter. PNC Financial Services Group Inc. now owns 4,419 shares of the biopharmaceutical company’s stock worth $147,000 after acquiring an additional 837 shares during the period.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.